Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Abstract Background Symptoms and comorbidities of ankylosing spondylitis (AS) considerably reduce health-related quality of life (HRQoL) and ability to work. This real-world study assessed rates of tumour necrosis factor inhibitor (TNFi) use and switching, treatment failure, and associations between...

Full description

Bibliographic Details
Main Authors: A. Deodhar, V. Strand, P. G. Conaghan, E. Sullivan, S. Blackburn, H. Tian, K. Gandhi, S. M. Jugl, R. Alten
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Rheumatology
Subjects:
Ankylosing spondylitis
DMARD
Quality of life
Tumour necrosis factor-alpha
Treatment failure
Online Access:http://link.springer.com/article/10.1186/s41927-020-0118-z

Internet

http://link.springer.com/article/10.1186/s41927-020-0118-z

Similar Items